Trading volume for Forward Pharma A/S – American D was 409K in the last trading session. Volume was up 636.27% over the stocks average daily volume. Investors are a little more bullish on Forward Pharma A/S – American D of late if you take note of the downtick in short interest. The stock recorded a fall in short interest between July 31, 2017 and August 15, 2017 of -15.23%. Short shares fell from 133,984 to 113,576 over that timeframe.
The following firms have recently changed their position in FWP. Eqis Capital Management, Inc. augmented its position by buying 4,097 shares an increase of 25.5% in the quarter. Eqis Capital Management, Inc. currently owns 20,178 shares worth $410,000. The total value of its holdings increased 18.5%. Drw Securities, LLC trimmed its holdings by selling 2,200 shares a decrease of 11.5% from 03/31/2017 to 06/30/2017. Drw Securities, LLC owns 17,000 shares valued at $346,000. The value of the position overall is down by 16.2%.
Senzar Asset Management, LLC cut its investment by shedding 445,500 shares a decrease of 96.6% as of 06/30/2017. Senzar Asset Management, LLC controls 15,600 shares with a value of $317,000. The value of the position overall is down by 96.8%. Bluemountain Capital Management, LLC expanded its ownership by buying 200,000 shares an increase of 15.3%. Bluemountain Capital Management, LLC now holds 1,511,043 shares valued at $26,982,000. The total value of its holdings decreased 4.5%.
The company is now down from yesterday’s close of 6.99.
Forward Pharma A/S, launched on July 1, 2005, is a clinical-stage biopharmaceutical company. The Company is involved in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Business’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis..